The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR.
Marr AR, et al. Among authors: mitchell ad.
Exp Hematol Oncol. 2024 Mar 4;13(1):27. doi: 10.1186/s40164-024-00483-w.
Exp Hematol Oncol. 2024.
PMID: 38438856
Free PMC article.